Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets s...
Main Authors: | , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2018
|
_version_ | 1797078322949128192 |
---|---|
author | Ternette, N Olde Nordkamp, M Muller, J Anderson, A Nicastri, A Hill, A Kessler, B Li, D |
author_facet | Ternette, N Olde Nordkamp, M Muller, J Anderson, A Nicastri, A Hill, A Kessler, B Li, D |
author_sort | Ternette, N |
collection | OXFORD |
description | The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analysed the immunopeptidomes of 6 HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 ). Immunopeptidomic profiling identified a total of 19,675 peptides from tumour and adjacent normal tissue and 130 of the peptides were found to have higher abundance in tumour than in normal tissues. To determine potential therapeutic target proteins, we calculated the average tumour-associated cohort coverage (aTaCC) that represents the percentage coverage of each protein in this cohort by peptides that had higher tumourial abundance. Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP) and ribophorin-2 (RPN-2) were found to have the highest aTaCC scores. We propose that these antigens could be evaluated further for their potential as targets in breast cancer immunotherapy and the small cohort immunopeptidomics analysis technique could be used in the wide spectrum of target discovery. This article is protected by copyright. All rights reserved. |
first_indexed | 2024-03-07T00:30:26Z |
format | Journal article |
id | oxford-uuid:7f986a73-f7c2-431d-a2a6-63084f58ce2c |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T00:30:26Z |
publishDate | 2018 |
publisher | Wiley |
record_format | dspace |
spelling | oxford-uuid:7f986a73-f7c2-431d-a2a6-63084f58ce2c2022-03-26T21:17:53ZImmunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigensJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f986a73-f7c2-431d-a2a6-63084f58ce2cEnglishSymplectic Elements at OxfordWiley2018Ternette, NOlde Nordkamp, MMuller, JAnderson, ANicastri, AHill, AKessler, BLi, DThe recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analysed the immunopeptidomes of 6 HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 ). Immunopeptidomic profiling identified a total of 19,675 peptides from tumour and adjacent normal tissue and 130 of the peptides were found to have higher abundance in tumour than in normal tissues. To determine potential therapeutic target proteins, we calculated the average tumour-associated cohort coverage (aTaCC) that represents the percentage coverage of each protein in this cohort by peptides that had higher tumourial abundance. Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP) and ribophorin-2 (RPN-2) were found to have the highest aTaCC scores. We propose that these antigens could be evaluated further for their potential as targets in breast cancer immunotherapy and the small cohort immunopeptidomics analysis technique could be used in the wide spectrum of target discovery. This article is protected by copyright. All rights reserved. |
spellingShingle | Ternette, N Olde Nordkamp, M Muller, J Anderson, A Nicastri, A Hill, A Kessler, B Li, D Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title | Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title_full | Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title_fullStr | Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title_full_unstemmed | Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title_short | Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens |
title_sort | immunopeptidomic profiling of hla a2 positive triple negative breast cancer identifies potential immunotherapy target antigens |
work_keys_str_mv | AT ternetten immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT oldenordkampm immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT mullerj immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT andersona immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT nicastria immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT hilla immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT kesslerb immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens AT lid immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens |